Amgen Completes Acquisition of Alantos
Amgen announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes as well as its matrix metalloproteinases platform for osteoarthritis. The acquisition was originally announced June 6.
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Genetically harmful compounds detected in vegetable oils - Genotoxins discovered for the first time using a novel method
REACH-IT - Online Inquiry Submission Now Available
Arkema invests in Specialty Acrylic Polymer production in China through its subsidiary Coatex

Life of zinc batteries drastically extended - Improvement to several 100,000 loads
Bionic coating could help ships to economize on fuel - Materials based on water ferns could reduce fuel consumption massively

Dow and Evonik announce startup of hydrogen peroxide to propylene glycol (HPPG) pilot plant - Innovative technology offer flexibility, lower costs, and a smaller environmental footprint

Waldner is expanding - Takeover of neighbouring company premises strengthens regional economy
